group included subjects whose IRLS scores were less than 10 after 4-week treatment, and the poor-responder group included those whose IRLS scores were 10 or over. (1) HAM-A scores were compared between the responder group and the poor-responder group. (2) In the poor-responder group, YKS was prescribed in combination with pramipexole. We also examined the effect of pramipexole and YKS (4 weeks) on IRLS, HAM-A, PSQI, and ESS. The local IRB approved this study. All patients gave written consent according to institutional guidelines and the tenets of the Declaration of Helsinki. Results: There was no difference in basal IRLS scores between two groups. The mean HAM-A score after pramipexole treatment in the poor-responder group (n=9) was higher than that in the responder group (n=24). Treatment with pramipexole and YKS for 4 weeks improved RLS and anxiety symptoms. Conclusions: Anxiety symptoms may affect the treatment outcome in patients with RLS. YKS was demonstrated to be effective for RLS and comorbid anxiety symptoms.
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Risk factors of insomnia in cancer patients who referred to psychoonoclogy clinic Changhyun Jang, Seok Joo Hong, Nam Hee Kim Ajou University Hospital, Republic of Korea Abstract Purpose: Insomnia is one of the most prevalent symptoms experienced by cancer patients. The goal of this study was to investigate the severity of insomnia and the risk factors of insomnia in cancer patients who referred to specialized psychooncology clinic. Method: A total of 167 cancer patients who referred to psychooncology clinic in Ajou University Hospital was investigated. Insomnia was measured using the Insomnia Severity Index (ISI). For the investigation of risk factors, we considered demographic factors, clinical factors, Distress Thermometer (DT), Functional Assessment of Cancer Therapy -General (FACT-G), and Hospital Anxiety and Depression Scale (HADS). The risk factors of insomnia were evaluated using multiple regression analysis. Results: Of 167 patients, 132 (79.0%) were females and 35 (21.0%) were males, with the average age at presentation of 51.1 years old. Most common cancers were breast (42.1%), gastrointestinal (16.4%), and gynecologic (18.4%). We defined insomnia group with over 15 score of ISI. Insomnia group (N=73, 43.7%) had more psychiatric past history and showed significantly higher distress, anxiety, and depression and lower physical, emotional, and social wellbeing than non-insomnia group. After adjusting the effect of psychiatric past history, the significant risk factors of insomnia were distress, anxiety, physical wellbeing, and social wellbeing and accounted for 38.7% of the variance in insomnia. Conclusion: Insomnia is prevalent in cancer patients who referred to psychooncology clinic. The modifiable risk factors of insomnia in these patients were distress, anxiety, physical wellbeing, and social wellbeing. Early assessment and intervention strategies for these factors could prevent from becoming chronic insomnia in cancer patients.
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Comparison of wearable activity tracker to actigraphy for sleep evaluation and circadian rhythm measurement. Medicine, 73 Inchon-ro, Seongbuk-gu, Seoul 136-705, Republic of Korea Tel: +82-2-920-5355, Fax: +82-2-927-2836, E-mail: leen54@chol.com Abstract Actigraphy has been used to assess sleep wake cycles for over 20 years. Recently, various wearable activity trackers that are synced wirelessly to smartphone are commonly used to promote health by general population. The purpose of this study was to evaluate the reliability and validity of wearable activity tracker (Fitbit charge HR) for sleep evaluation and circadian rhythm measurement compared to actigraphy (Actiwatch 2). We compared wearable activity tracker and actigraphy for sleep and activity variables and circadian rhythm. 16 healthy adults wore Fitbit charge HR and Actiwatch 2 simultaneously on the same wrist. Also, participants went about their daily life and recorded sleep log during a 14-day period. The validity was assessed by comparing the output using Wilcoxon signed rank tests and Spearman's correlation. For sleep variables, both sleep start time (r=0.869, p<0.001) and sleep duration (r=0.918, p<0.001) are highly correlated between the two devices. However, Fitbit charge HR tends to overestimate sleep duration compared to actigraphy (mean±SD 409.7 ± 97.6 vs 387.3 ± 98.3). Although activity score showed low correlation between the two devices, period (r=0.800, p<0.001) and acrophase (r=0.980, p<0.001) of the circadian rhythm using Cosinor analysis are highly correlated. Fitbit charge HR showed strong validity for measurement of sleep variables and estimation of circadian rhythm. The results suggest that Fitbit charge HR can be used alternatively to measure sleep and circadian rhythm for psychiatric disorders, especially mood disorders. 
Abstract
Disturbed sleep_ENREF_23_ENREF_23 has been _ENREF_27 associated with increased insulin resistance in previous studies and there is growing body of evidence that activation of inflammatory pathways plays a crucial role in the development of insulin resistance. This study aimed to examine associations between objectively measured sleep, inflammatory markers and insulin resistance.
Cross-sectional data collected from 2004 to 2009 during the Midlife Development in the U.S. II (MIDUS II) biomarker project were used. The study was performed in the MIDUS Research Center at the University of Wisconsin-Madison and participants' homes. The study population included 374 community-based midlife subjects (138 men and 236 women) who completed 7 nights of wrist actigraphy. The mean age was 54.3 years (range 34 to 83).
To reveal factors associated with insulin resistance and age, statistically significant variables in univariate regression analyses were entered into multivariate regression analyses. Insulin resistance was estimated by homeostasis model assessment of insulin resistance (HOMA-IR). In women, higher sleep onset latency (SOL) was associated with higher insulin resistance after adjustment for possible confounding factors including age, smoking, obesity, diabetes, depression, and inflammatory cytokines. Also, higher SOL was associated with higher interleukin (IL)-6 and C-reactive protein (CRP) levels. After adjusting for covariates, no sleep measures were associated with insulin resistance, IL-6, or CRP in men. The mediation analysis showed that higher SOL is associated with insulin resistance both directly and indirectly.
Difficulty initiating sleep contributes to insulin resistance development, especially in middle-aged women. A combination of inflammatory pathway activation and physiological hyperarousal may be one of the key underlying mechanisms.
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Prevalence Abstract Background: Professional fire fighter is a strenuous and unique occupation due to the high levels of stress and risk involved as well as the low control nature of the job. Anxiety and depression are prevalent in the professional fire fighters' population and constitute a dominant area of investigation. Limited attention have been given to impact of sleep problems on the anxiety, depression and quality of life in fire fighters. The aim of this study is to evaluate prevalence of sleep problems and its impact on anxiety, depression and quality of life in Korean fire fighters. Methods: Using simple sampling method in a cross-section study in Jeonbuk province of Korea, sleep problems, anxiety, depression and quality of life of 1669 professional fire fighters were measured with Patients Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder 7 item (GAD-7) and brief version of World Health Organization Quality of Life assessment scale (WHOQoL-Brief). Sleep problem was measured with 3 item of PHQ-9, the definition of sleep problems group was not able to initiate sleep or maintaining sleep. We measured cross-sectional Odds ratios for sleep problems group on depression and anxiety by logistic regression analysis. Results: The prevalence of sleep problem of Korean fire fighters was 51.2%. Korean fire fighters with sleep problems showed not only more anxiety (p<0.001) and depression(p<0.001) but also lower quality of life (p<0.001). The sleep problems group was more likely to suffer from depression (OR=47.537,95%, Cl: 33.669-64.323) and anxiety (OR=9.822, 95%, Cl: 7.529-12.813). The severity of sleep problems in Korean fire fighters was positive correlated with depression and anxiety. Conclusion: These results show that higher prevalence of sleep problems in Korean fire fighters and Korean fire fighters with sleep problems have more depression and anxiety, and less quality of life than fire fighters with\-out sleep problems. Sleep problems are important risk factor on the depression and anxiety in Korean fire fighters. Early detect of sleep problems of fire fighters will be needed to manage of depression and anxiety'. Key Words: Insomnia, Prevalence, Anxiety, Depression, QoL, Fire fighter.
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Check an effeciency About the Suvorexant with Combining Other Sleep Promoting Medicines Toshiaka Tsuneoka Akira Iwanami, Sayaka Matsuzaki, Haruhisa Ohta, Nobuyuki Saga, Hiroki Sasamori, Hiroki Yamada, Sachiko Yokoyama Showa University, Japan Abstract Background: Suvorexant was launched on November 26, 2014 in Japan. This is marketed as the world's first orexin receptor antagonist to treat insomnia. Orexins is synthesized by neurons in hypothalamus, and promote arousal by acting on the orexin receptors in the arousal center.
Suvorexant promotes sleep by blocking orexin neuropeptides from binding to their receptors. So far, the effects and the side effects have been reported for patients administrated suvorexant alone. There are no reports of effects and side effects of suvorexant combining to other hypnotics. However, suvorexant is often used combining with other sleep promoting medicines such as benzodiazepines and major tranquilizers in psychiatric hospitals. We investigated 116 combined use cases from medical records in Showa University Karasuyama Hospital, Tokyo, Japan, to check an usefulness and a safety about the suvorexant when combining with other sleep promoting medicines. We also investigated the characteristics of patients with insufficient effect of orexin. Result: The diagnoses of patients who received a combination of suvorexant and other sleep promoting medicines in our hospital from December 2014 to September 2015 were schizophrenia (13％), mood disorder (21％)、addiction include alcoholic (8.6％).
62 subjects (54%) continued to take suvorexant over 3 months. 20 subjects(17%) and 23subjects (20%) stop taking orexin due to the side effect and the insufficient effect respectively. 40 subjects (35%) had better effect than other medicines.
Conclusion:
The result suggested that combined use of suvorexant and other psychotropic medicine were effective and safe for patients with schizophrenia, mood disorder and alcoholic who took benzodiazepines or major tranquilizers.
On the other hand, the suvorexant was ineffective for a part of patients. A further investigation will be needed for the ineffective cases.
The first limitation of this study was that this study investigated the effect and the side effect of suvorexant only by medical records so that we did not notice symptoms without description on the records. The second limitation was that we could not concern about placebo effect
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Nicotine evokes convulsive seizures by activating amygdala neurons partly through α7nACh receptors Higor A. Iha, Naofumi Kunisawa, Saki Shimizu, Yuto Mizuguchi, Takanori Nohara, Yudai Atsuta, Keito Yoshikawa, Kentaro Tokudome, Masato Kinboshi, Tadao Serikawa and Yukihiro Ohno Osaka University of Pharmaceutical Sciences
